Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer

Nutrition and Cancer

Volumn 65, Issue SUPPL.1, 2013, Pages 3-11

  Mateen, Samiha ^a   Raina, Komal ^a   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ERLOTINIB; SILIBININ;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MONOTHERAPY; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; SILYMARIN;

EID: 84878537775     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.785004     Document Type: Conference Paper

References (68)

1. Amercian Cancer Society. 2012. Cancer Facts and Figures.
2. Denlinger, C E, Ikonomidis, J S, Reed, C E, and, Spinale, F G. 2010. Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg, 140: 505-513.
3. Travis, W D. 2011. Classification of lung cancer. Semin Roentgenol, 46: 178-186.
4. Schiller, J H. 2001. Current standards of care in small-cell and non-small-cell lung cancer. Oncology, 61 (1): 3-13.
5. Collins, L G, Haines, C, Perkel, R, and, Enck, R E. 2007. Lung cancer: diagnosis and management. Am Fam Physician, 75: 56-63. (Pubitemid 46064483)
6. Spira, A, and, Ettinger, D S. 2004. Multidisciplinary management of lung cancer. N Engl J Med, 350: 379-392. (Pubitemid 38101633)
7. Mountain, C F. 1997. Revisions in the International System for Staging Lung Cancer. Chest, 111: 1710-1717. (Pubitemid 27260107)
8. Molina, J R, Yang, P, Cassivi, S D, Schild, S E, and, Adjei, A A. 2008. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83: 584-594. (Pubitemid 351720831)
9. Molina, J R, Adjei, A A, and, Jett, J R. 2006. Advances in chemotherapy of non-small cell lung cancer. Chest, 130: 1211-1219. (Pubitemid 44583755)
10. Sorenson, S, Glimelius, B, and, Nygren, P. 2001. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol, 40: 327-339. (Pubitemid 32588126)
11. DAddario, G, Pintilie, M, Leighl, N B, Feld, R, Cerny, T. 2005. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol, 23: 2926-2936. (Pubitemid 46224111)
12. Sun, S, Schiller, J H, Spinola, M, and, Minna, J D. 2007. New molecularly targeted therapies for lung cancer. J Clin Invest, 117: 2740-2750. (Pubitemid 47529602)
13. Burris, H A 3rd. 2009. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene, 28 (1): S4-13.
14. Giaccone, G. 2004. Twenty-five years of treating advanced NSCLC: what have we achieved?. Ann Oncol, 15 (4): 81-83.
15. Neal, J W, and, Sequist, L V. 2010. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol, 11: 36-44.
16. Sangha, R, Lara, P N Jr., Mack, P C, and, Gandara, D R. 2009. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol, 21: 116-123.
17. Surh, Y J. 2003. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer, 3: 768-780.
18. Cohen, V, and, Khuri, F R. 2003. Progress in lung cancer chemoprevention. Cancer Control, 10: 315-324. (Pubitemid 36919544)
19. Cohen, V, and, Khuri, F R. 2004. Chemoprevention of lung cancer. Curr Opin Pulm Med, 10: 279-283. (Pubitemid 38803120)
20. Soria, J C, Kim, E S, Fayette, J, Lantuejoul, S, Deutsch, E. 2003. Chemoprevention of lung cancer. Lancet Oncol, 4: 659-669. (Pubitemid 37407433)
21. Sporn, M B. 1993. Chemoprevention of cancer. Lancet, 342: 1211-1213. (Pubitemid 23331714)
22. Russo, G L. 2007. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol, 74: 533-544. (Pubitemid 47042006)
23. Tsao, A S, Kim, E S, and, Hong, W K. 2004. Chemoprevention of cancer. CA Cancer J Clin, 54: 150-180. (Pubitemid 38812180)
24. van Zandwijk, N, and, Hirsch, F R. 2003. Chemoprevention of lung cancer: current status and future prospects. Lung Cancer, 42 (1): S71-79.
25. Mehta, R G, Murillo, G, Naithani, R, and, Peng, X. 2010. Cancer chemoprevention by natural products: how far have we come?. Pharm Res, 27: 950-961.
26. Omenn, G S. 2007. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Eur J Cancer Prev, 16: 184-191. (Pubitemid 46597421)
27. Omenn, G S. 2004. Human lung cancer chemoprevention strategies: Parker B. Francis lecture. Chest, 125: 123S-127S. (Pubitemid 38648348)
28. Winterhalder, R C, Hirsch, F R, Kotantoulas, G K, Franklin, W A, and, Bunn, P A Jr. 2004. Chemoprevention of lung cancer-from biology to clinical reality. Ann Oncol, 15: 185-196. (Pubitemid 38262613)
29. Cohen, V, and, Khuri, F R. 2002. Chemoprevention of lung cancer: current status and future prospects. Cancer Metastasis Rev, 21: 349-362. (Pubitemid 36071920)
30. Lam, S, McWilliams, A, LeRiche, J, MacAulay, C, Wattenberg, L. 2006. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev, 15: 1526-1531. (Pubitemid 44299327)
31. Lippman, S M, Lee, J J, Karp, D D, Vokes, E E, Benner, S E. 2001. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst, 93: 605-618.
32. Kim, K W, Choi, C H, Kim, T H, Kwon, C H, Woo, J S. 2009. Silibinin inhibits glioma cell proliferation via Ca2+/ROS/MAPK-dependent mechanism in vitro and glioma tumor growth in vivo. Neurochem Res, 34: 1479-1490.
33. Keith, R L. 2009. Chemoprevention of lung cancer. Proc Am Thorac Soc, 6: 187-193.
34. Ramasamy, K, and, Agarwal, R. 2008. Multitargeted therapy of cancer by silymarin. Cancer Lett, 269: 352-362.
35. Singh, R P, and, Agarwal, R. 2004. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets, 4: 1-11. (Pubitemid 38332560)
36. Singh, R P, and, Agarwal, R. 2005. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer, 41: 1969-1979. (Pubitemid 41557682)
37. Singh, R P, and, Agarwal, R. 2006. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog, 45: 436-442. (Pubitemid 43865852)
38. Agarwal, R, Agarwal, C, Ichikawa, H, Singh, R P, and, Aggarwal, B B. 2006. Anticancer potential of silymarin: from bench to bed side. Anticancer Res, 26: 4457-4498. (Pubitemid 46031522)
39. Post-White, J, Ladas, E J, and, Kelly, K M. 2007. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther, 6: 104-109. (Pubitemid 46871842)
40. Pradhan, S C, and, Girish, C. 2006. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res, 124: 491-504. (Pubitemid 46157708)
41. Rainone, F. 2005. Milk thistle. Am Fam Physician, 72: 1285-1288. (Pubitemid 43104260)
42. Kroll, D J, Shaw, H S, and, Oberlies, N H. 2007. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther, 6: 110-119. (Pubitemid 46871844)
43. Chittezhath, M, Deep, G, Singh, R P, Agarwal, C, and, Agarwal, R. 2008. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther, 7: 1817-1826.
44. Mateen, S, Tyagi, A, Agarwal, C, Singh, R P, and, Agarwal, R. 2010. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog, 49: 247-258.
45. -/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res, 17: 753-761.
46. Singh, R P, Deep, G, Chittezhath, M, Kaur, M, Dwyer-Nield, L D. 2006. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst, 98: 846-855. (Pubitemid 43923441)
47. Tyagi, A, Agarwal, C, Dwyer-Nield, L D, Singh, R P, Malkinson, A M. 2011. Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog
48. Sharma, G, Singh, R P, Chan, D C, and, Agarwal, R. 2003. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res, 23: 2649-2655. (Pubitemid 36897139)
49. Deep, G, and, Agarwal, R. 2010. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev, 29: 447-463.
50. Raina, K, Rajamanickam, S, Singh, R P, Deep, G, Chittezhath, M. 2008. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res, 68: 6822-6830.
51. Chen, P N, Hsieh, Y S, Chiang, C L, Chiou, H L, Yang, S F. 2006. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res, 85: 220-225.
52. Chu, S C, Chiou, H L, Chen, P N, Yang, S F, and, Hsieh, Y S. 2004. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog, 40: 143-149.
53. Singh, R P, Mallikarjuna, G U, Sharma, G, Dhanalakshmi, S, Tyagi, A K. 2004. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res, 10: 8641-8647. (Pubitemid 40053432)
54. Rho, J K, Choi, Y J, Jeon, B S, Choi, S J, Cheon, G J. 2010. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther, 9: 3233-3243.
55. Tyagi, A, Singh, R P, Ramasamy, K, Raina, K, Redente, E F. 2009. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila), 2: 74-83.
56. Dagne, A, Melkamu, T, Schutten, M M, Qian, X, Upadhyaya, P. 2011. Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice. Carcinogenesis, 32: 561-567.
57. Yan, Y, Wang, Y, Tan, Q, Lubet, R A, and, You, M. 2005. Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia, 7: 1053-1057. (Pubitemid 44430983)
58. Belinsky, S A, Klinge, D M, Stidley, C A, Issa, J P, Herman, J G. 2003. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res, 63: 7089-7093. (Pubitemid 37413444)
59. Jones, P A, and, Baylin, S B. 2007. The epigenomics of cancer. Cell, 128: 683-692. (Pubitemid 46273572)
60. Risch, A, and, Plass, C. 2008. Lung cancer epigenetics and genetics. Int J Cancer, 123: 1-7. (Pubitemid 351705185)
61. Mateen, S, Raina, K, Agarwal, C, and, Agarwal, R. Inhibition of Epigenetic Chromatin-Modification Enzymes: Histone Deacetylases and DNA Methyltransferases by Silibinin in human NSCLC H1299 cells. 101 st Annual Meeting of AACR, Washington, D.C., USA. April (abstr)
62. Witt, O, Deubzer, H E, Milde, T, and, Oehme, I. 2009. HDAC family: What are the cancer relevant targets?. Cancer Lett, 277: 8-21.
63. Bots, M, and, Johnstone, R W. 2009. Rational combinations using HDAC inhibitors. Clin Cancer Res, 15: 3970-3977.
64. Song, S H, Han, S W, and, Bang, Y J. 2011. Epigenetic-based therapies in cancer: progress to date. Drugs, 71: 2391-2403.
65. Mateen, S, Raina, K, Jain, A K, Agarwal, C, Chan, D, and, Agarwal, R. 2012. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics, 7: 1161-1172.
66. Mateen, S, Raina, K, Agarwal, C, Chan, D, and, Agarwal, R. 2013. Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Upregulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells. The Journal of pharmacology and experimental therapeutics, 345: 206-214.
67. Witta, S E, Gemmill, R M, Hirsch, F R, Coldren, C D, Hedman, K. 2006. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res, 66: 944-950. (Pubitemid 43165962)
68. Richardson, F, Young, G D, Sennello, R, Wolf, J, Argast, G M. 2012. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res, 32: 537-552.